The nitric oxide synthase-1 and nitric oxide synthase-3/nitric oxide signalling systems in the heart of wild type mice and mouse mutants.

Histochem J

Department of Anatomy II, University Clinic Benjamin Franklin, Free University of Berlin, Königin-Luise-Str. 15, D-14195 Berlin, Germany.

Published: January 2004

Recently, we have shown that nitric oxide synthase-1 (NOS-1) and thus its product NO are present in the sarcolemma region of a subpopulation of atrial cardiomyocytes in the rat heart. In order to find out whether this newly discovered sarcolemma-associated NOS/NO system represents a general signalling mechanism in the murine rodent heart and whether its properties are comparable to those in skeletal muscle fibres, immunohistochemical and catalytic histochemical methods (including image analysis) were applied to the heart and extensor digitorum longus (EDL) and tongue muscles of wild type and mutant mice. In different strains of wild type mice and NOS-3 knockouts, urea-resistant (and therefore specific) NOS NADPH diaphorase histochemistry and NOS-1 immunohistochemistry revealed that NOS-1 activity and protein were present in the sarcolemma region of a subpopulation of atrial and ventricular working cardiomyocytes, but not in those of the impulse conducting system. Using image analysis, NOS-1 showed similar activities in the sarcolemma region of cardiomyocytes and in EDL type I myofibres. In mdx and NOS-1 knockout mice, NOS-1 was absent from the sarcolemma region of atrial and ventricular cardiomyocytes and of EDL and tongue muscle fibres, whereas NOS-1 was present in the hearts of NOS-3 knockouts. Atrial natriuretic peptide immunohistochemistry identified part of the atrial NOS-1-expressing cardiomyocytes as myoendocrine cells. In mdx mice as well as in NOS-1 - and NOS-3-deficient animals, the peptide was found in greater abundance than in wild type mice. These data suggest that NOS-1 is expressed in a subpopulation of working cardiomyocytes in the murine rodent heart, that the myoendocrine cells may be negatively modulated by NOS-1 - and NOS-3-produced NO, and that the anchoring mechanisms for NOS-1 in these cells (i.e. their confinement to the sarcolemma region) are comparable to those in skeletal muscle fibres.

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1023390811358DOI Listing

Publication Analysis

Top Keywords

sarcolemma region
20
wild type
16
nitric oxide
12
type mice
12
muscle fibres
12
nos-1
11
oxide synthase-1
8
region subpopulation
8
subpopulation atrial
8
murine rodent
8

Similar Publications

Sonogenetics is a novel antiarrhythmic mechanism.

Chaos

January 2025

School of Physics and Information Technology, Shaanxi Normal University, Xi'an 710062, China.

Arrhythmia of the heart is a dangerous and potentially fatal condition. The current widely used treatment is the implantable cardioverter defibrillator (ICD), but it is invasive and affects the patient's quality of life. The sonogenetic mechanism proposed here focuses ultrasound on a cardiac tissue, controls endogenous stretch-activated Piezo1 ion channels on the focal region's cardiomyocyte sarcolemma, and restores normal heart rhythm.

View Article and Find Full Text PDF

Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan.

Skelet Muscle

January 2025

Department of Molecular Physiology and Biophysics, and Department of Neurology, Howard Hughes Medical Institute, Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, Roy J. and Lucille A. Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA.

Background: Maintaining the connection between skeletal muscle fibers and the surrounding basement membrane is essential for muscle function. Dystroglycan (DG) serves as a basement membrane extracellular matrix (ECM) receptor in many cells, and is also expressed in the outward-facing membrane, or sarcolemma, of skeletal muscle fibers. DG is a transmembrane protein comprised of two subunits: alpha-DG (α-DG), which resides in the peripheral membrane, and beta-DG (β-DG), which spans the membrane to intracellular regions.

View Article and Find Full Text PDF

Biophysical characterization of the dystrophin C-terminal domain: Dystrophin interacts differentially with dystrobrevin isoforms.

J Biol Chem

December 2024

Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Electronic address:

Article Synopsis
  • Duchenne muscular dystrophy (DMD) is caused by a mutation in the dystrophin gene, leading to a lack of functional dystrophin protein, resulting in muscle degeneration, and although some targeted therapies exist, they have limited effectiveness and are expensive.
  • The structure and function of the C-terminal (CT) domain of dystrophin, which interacts with dystrobrevin to stabilize muscle cell membranes, are not well understood, posing challenges for treatment development.
  • Research indicates that the CT domain is non-globular and interacts differently with two isoforms of dystrobrevin, revealing how variations in their amino acid composition can affect the stability of the dystrophin-associated glycoprotein
View Article and Find Full Text PDF

Deficiency of muscle-generated brain-derived neurotrophic factor causes inflammatory myopathy through reactive oxygen species-mediated necroptosis and pyroptosis.

Redox Biol

December 2024

School of Biological Sciences, Faculty of Science, The University of Hong Kong, Hong Kong Special Administrative Region; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong Special Administrative Region. Electronic address:

Idiopathic inflammatory myopathy (commonly known as myositis) is a group of immune-related diseases characterized by muscle damage, weakness, and fatigue with unknown causes. Although overactivated innate immunity is a widely believed cause of myositis onset, the mechanism that provokes and maintains a high immune response in myositis patients is still unclear. This study aims to test if brain-derived neurotrophic factor (BDNF) deficiency per se is sufficient to cause myositis and determine its underlying mechanism.

View Article and Find Full Text PDF

Detection of pTDP-43 via routine muscle biopsy: A promising diagnostic biomarker for amyotrophic lateral sclerosis.

Brain Pathol

November 2024

Department of Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Article Synopsis
  • - Amyotrophic lateral sclerosis (ALS) is marked by TDP-43 protein aggregates, and the study investigates whether detecting phosphorylated TDP-43 (pTDP-43) in muscle biopsies can help diagnose ALS more effectively.
  • - The research involved muscle biopsies from 18 ALS patients and 54 non-ALS controls, revealing that 94.4% of ALS patients had abnormal pTDP-43 aggregation compared to 29.6% of controls, indicating a strong correlation.
  • - The findings suggest that pTDP-43 accumulation is detectable in muscle tissues before clinical symptoms appear, potentially making it a valuable diagnostic biomarker for early ALS detection.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!